Global Antibody-radionuclide Conjugates Market Research Report 2024, Forecast to 2032
Report Overview
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Antibody-radionuclide Conjugates market size was estimated at USD 1042.80 million in 2023 and is projected to reach USD 4417.88 million by 2032, exhibiting a CAGR of 17.40% during the forecast period.
North America Antibody-radionuclide Conjugates market size was estimated at USD 358.82 million in 2023, at a CAGR of 14.91% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Antibody-radionuclide Conjugates market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antibody-radionuclide Conjugates Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antibody-radionuclide Conjugates market in any manner.
Global Antibody-radionuclide Conjugates Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Market Segmentation (by Type)
Beta-emitting
Targeted Alpha Therapy
Market Segmentation (by Application)
Solid Tumor
Non Hodgkin Lymphoma
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody-radionuclide Conjugates Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antibody-radionuclide Conjugates, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
Antibody-radionuclide Conjugates is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Antibody-radionuclide Conjugates market size was estimated at USD 1042.80 million in 2023 and is projected to reach USD 4417.88 million by 2032, exhibiting a CAGR of 17.40% during the forecast period.
North America Antibody-radionuclide Conjugates market size was estimated at USD 358.82 million in 2023, at a CAGR of 14.91% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Antibody-radionuclide Conjugates market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antibody-radionuclide Conjugates Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antibody-radionuclide Conjugates market in any manner.
Global Antibody-radionuclide Conjugates Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Market Segmentation (by Type)
Beta-emitting
Targeted Alpha Therapy
Market Segmentation (by Application)
Solid Tumor
Non Hodgkin Lymphoma
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Antibody-radionuclide Conjugates Market
- Overview of the regional outlook of the Antibody-radionuclide Conjugates Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody-radionuclide Conjugates Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Antibody-radionuclide Conjugates, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Antibody-radionuclide Conjugates
1.2 Key Market Segments
1.2.1 Antibody-radionuclide Conjugates Segment by Type
1.2.2 Antibody-radionuclide Conjugates Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antibody-radionuclide Conjugates Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Antibody-radionuclide Conjugates Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET COMPETITIVE LANDSCAPE
3.1 Global Antibody-radionuclide Conjugates Sales by Manufacturers (2019-2024)
3.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Manufacturers (2019-2024)
3.3 Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antibody-radionuclide Conjugates Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antibody-radionuclide Conjugates Sales Sites, Area Served, Product Type
3.6 Antibody-radionuclide Conjugates Market Competitive Situation and Trends
3.6.1 Antibody-radionuclide Conjugates Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antibody-radionuclide Conjugates Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTIBODY-RADIONUCLIDE CONJUGATES INDUSTRY CHAIN ANALYSIS
4.1 Antibody-radionuclide Conjugates Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTIBODY-RADIONUCLIDE CONJUGATES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)
6.3 Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2019-2024)
6.4 Global Antibody-radionuclide Conjugates Price by Type (2019-2024)
7 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antibody-radionuclide Conjugates Market Sales by Application (2019-2024)
7.3 Global Antibody-radionuclide Conjugates Market Size (M USD) by Application (2019-2024)
7.4 Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
8 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET CONSUMPTION BY REGION
8.1 Global Antibody-radionuclide Conjugates Sales by Region
8.1.1 Global Antibody-radionuclide Conjugates Sales by Region
8.1.2 Global Antibody-radionuclide Conjugates Sales Market Share by Region
8.2 North America
8.2.1 North America Antibody-radionuclide Conjugates Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antibody-radionuclide Conjugates Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antibody-radionuclide Conjugates Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antibody-radionuclide Conjugates Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antibody-radionuclide Conjugates Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET PRODUCTION BY REGION
9.1 Global Production of Antibody-radionuclide Conjugates by Region (2019-2024)
9.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)
9.3 Global Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Antibody-radionuclide Conjugates Production
9.4.1 North America Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.4.2 North America Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Antibody-radionuclide Conjugates Production
9.5.1 Europe Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.5.2 Europe Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Antibody-radionuclide Conjugates Production (2019-2024)
9.6.1 Japan Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.6.2 Japan Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Antibody-radionuclide Conjugates Production (2019-2024)
9.7.1 China Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.7.2 China Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Bayer
10.1.1 Bayer Antibody-radionuclide Conjugates Basic Information
10.1.2 Bayer Antibody-radionuclide Conjugates Product Overview
10.1.3 Bayer Antibody-radionuclide Conjugates Product Market Performance
10.1.4 Bayer Business Overview
10.1.5 Bayer Antibody-radionuclide Conjugates SWOT Analysis
10.1.6 Bayer Recent Developments
10.2 Novartis
10.2.1 Novartis Antibody-radionuclide Conjugates Basic Information
10.2.2 Novartis Antibody-radionuclide Conjugates Product Overview
10.2.3 Novartis Antibody-radionuclide Conjugates Product Market Performance
10.2.4 Novartis Business Overview
10.2.5 Novartis Antibody-radionuclide Conjugates SWOT Analysis
10.2.6 Novartis Recent Developments
10.3 Lantheus
10.3.1 Lantheus Antibody-radionuclide Conjugates Basic Information
10.3.2 Lantheus Antibody-radionuclide Conjugates Product Overview
10.3.3 Lantheus Antibody-radionuclide Conjugates Product Market Performance
10.3.4 Lantheus Antibody-radionuclide Conjugates SWOT Analysis
10.3.5 Lantheus Business Overview
10.3.6 Lantheus Recent Developments
10.4 Aurobindo Pharma
10.4.1 Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information
10.4.2 Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview
10.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product Market Performance
10.4.4 Aurobindo Pharma Business Overview
10.4.5 Aurobindo Pharma Recent Developments
10.5 Mundipharma
10.5.1 Mundipharma Antibody-radionuclide Conjugates Basic Information
10.5.2 Mundipharma Antibody-radionuclide Conjugates Product Overview
10.5.3 Mundipharma Antibody-radionuclide Conjugates Product Market Performance
10.5.4 Mundipharma Business Overview
10.5.5 Mundipharma Recent Developments
10.6 China Isotope and Radiation
10.6.1 China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information
10.6.2 China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview
10.6.3 China Isotope and Radiation Antibody-radionuclide Conjugates Product Market Performance
10.6.4 China Isotope and Radiation Business Overview
10.6.5 China Isotope and Radiation Recent Developments
10.7 Curium Pharmaceuticals
10.7.1 Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.7.2 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.7.4 Curium Pharmaceuticals Business Overview
10.7.5 Curium Pharmaceuticals Recent Developments
10.8 Gilead Sciences
10.8.1 Gilead Sciences Antibody-radionuclide Conjugates Basic Information
10.8.2 Gilead Sciences Antibody-radionuclide Conjugates Product Overview
10.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product Market Performance
10.8.4 Gilead Sciences Business Overview
10.8.5 Gilead Sciences Recent Developments
10.9 Clarity Pharmaceuticals
10.9.1 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.9.2 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.9.4 Clarity Pharmaceuticals Business Overview
10.9.5 Clarity Pharmaceuticals Recent Developments
10.10 Curasight
10.10.1 Curasight Antibody-radionuclide Conjugates Basic Information
10.10.2 Curasight Antibody-radionuclide Conjugates Product Overview
10.10.3 Curasight Antibody-radionuclide Conjugates Product Market Performance
10.10.4 Curasight Business Overview
10.10.5 Curasight Recent Developments
10.11 Nordic Nanovector
10.11.1 Nordic Nanovector Antibody-radionuclide Conjugates Basic Information
10.11.2 Nordic Nanovector Antibody-radionuclide Conjugates Product Overview
10.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product Market Performance
10.11.4 Nordic Nanovector Business Overview
10.11.5 Nordic Nanovector Recent Developments
10.12 Philogen
10.12.1 Philogen Antibody-radionuclide Conjugates Basic Information
10.12.2 Philogen Antibody-radionuclide Conjugates Product Overview
10.12.3 Philogen Antibody-radionuclide Conjugates Product Market Performance
10.12.4 Philogen Business Overview
10.12.5 Philogen Recent Developments
10.13 RadioMedix
10.13.1 RadioMedix Antibody-radionuclide Conjugates Basic Information
10.13.2 RadioMedix Antibody-radionuclide Conjugates Product Overview
10.13.3 RadioMedix Antibody-radionuclide Conjugates Product Market Performance
10.13.4 RadioMedix Business Overview
10.13.5 RadioMedix Recent Developments
10.14 Telix Pharmaceuticals
10.14.1 Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.14.2 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.14.4 Telix Pharmaceuticals Business Overview
10.14.5 Telix Pharmaceuticals Recent Developments
10.15 Orano Med
10.15.1 Orano Med Antibody-radionuclide Conjugates Basic Information
10.15.2 Orano Med Antibody-radionuclide Conjugates Product Overview
10.15.3 Orano Med Antibody-radionuclide Conjugates Product Market Performance
10.15.4 Orano Med Business Overview
10.15.5 Orano Med Recent Developments
10.16 Actinium Pharmaceuticals
10.16.1 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.16.2 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.16.4 Actinium Pharmaceuticals Business Overview
10.16.5 Actinium Pharmaceuticals Recent Developments
10.17 Y-mAbs Therapeutics
10.17.1 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
10.17.2 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
10.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Market Performance
10.17.4 Y-mAbs Therapeutics Business Overview
10.17.5 Y-mAbs Therapeutics Recent Developments
10.18 Fusion Pharmaceuticals
10.18.1 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.18.2 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.18.4 Fusion Pharmaceuticals Business Overview
10.18.5 Fusion Pharmaceuticals Recent Developments
11 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET FORECAST BY REGION
11.1 Global Antibody-radionuclide Conjugates Market Size Forecast
11.2 Global Antibody-radionuclide Conjugates Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antibody-radionuclide Conjugates Market Size Forecast by Country
11.2.3 Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region
11.2.4 South America Antibody-radionuclide Conjugates Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Antibody-radionuclide Conjugates by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Antibody-radionuclide Conjugates Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Antibody-radionuclide Conjugates by Type (2025-2032)
12.1.2 Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Antibody-radionuclide Conjugates by Type (2025-2032)
12.2 Global Antibody-radionuclide Conjugates Market Forecast by Application (2025-2032)
12.2.1 Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by Application
12.2.2 Global Antibody-radionuclide Conjugates Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Antibody-radionuclide Conjugates
1.2 Key Market Segments
1.2.1 Antibody-radionuclide Conjugates Segment by Type
1.2.2 Antibody-radionuclide Conjugates Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Antibody-radionuclide Conjugates Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Antibody-radionuclide Conjugates Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET COMPETITIVE LANDSCAPE
3.1 Global Antibody-radionuclide Conjugates Sales by Manufacturers (2019-2024)
3.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Manufacturers (2019-2024)
3.3 Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antibody-radionuclide Conjugates Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Antibody-radionuclide Conjugates Sales Sites, Area Served, Product Type
3.6 Antibody-radionuclide Conjugates Market Competitive Situation and Trends
3.6.1 Antibody-radionuclide Conjugates Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antibody-radionuclide Conjugates Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ANTIBODY-RADIONUCLIDE CONJUGATES INDUSTRY CHAIN ANALYSIS
4.1 Antibody-radionuclide Conjugates Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ANTIBODY-RADIONUCLIDE CONJUGATES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)
6.3 Global Antibody-radionuclide Conjugates Market Size Market Share by Type (2019-2024)
6.4 Global Antibody-radionuclide Conjugates Price by Type (2019-2024)
7 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antibody-radionuclide Conjugates Market Sales by Application (2019-2024)
7.3 Global Antibody-radionuclide Conjugates Market Size (M USD) by Application (2019-2024)
7.4 Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
8 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET CONSUMPTION BY REGION
8.1 Global Antibody-radionuclide Conjugates Sales by Region
8.1.1 Global Antibody-radionuclide Conjugates Sales by Region
8.1.2 Global Antibody-radionuclide Conjugates Sales Market Share by Region
8.2 North America
8.2.1 North America Antibody-radionuclide Conjugates Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antibody-radionuclide Conjugates Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antibody-radionuclide Conjugates Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antibody-radionuclide Conjugates Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antibody-radionuclide Conjugates Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET PRODUCTION BY REGION
9.1 Global Production of Antibody-radionuclide Conjugates by Region (2019-2024)
9.2 Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)
9.3 Global Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Antibody-radionuclide Conjugates Production
9.4.1 North America Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.4.2 North America Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Antibody-radionuclide Conjugates Production
9.5.1 Europe Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.5.2 Europe Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Antibody-radionuclide Conjugates Production (2019-2024)
9.6.1 Japan Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.6.2 Japan Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Antibody-radionuclide Conjugates Production (2019-2024)
9.7.1 China Antibody-radionuclide Conjugates Production Growth Rate (2019-2024)
9.7.2 China Antibody-radionuclide Conjugates Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 Bayer
10.1.1 Bayer Antibody-radionuclide Conjugates Basic Information
10.1.2 Bayer Antibody-radionuclide Conjugates Product Overview
10.1.3 Bayer Antibody-radionuclide Conjugates Product Market Performance
10.1.4 Bayer Business Overview
10.1.5 Bayer Antibody-radionuclide Conjugates SWOT Analysis
10.1.6 Bayer Recent Developments
10.2 Novartis
10.2.1 Novartis Antibody-radionuclide Conjugates Basic Information
10.2.2 Novartis Antibody-radionuclide Conjugates Product Overview
10.2.3 Novartis Antibody-radionuclide Conjugates Product Market Performance
10.2.4 Novartis Business Overview
10.2.5 Novartis Antibody-radionuclide Conjugates SWOT Analysis
10.2.6 Novartis Recent Developments
10.3 Lantheus
10.3.1 Lantheus Antibody-radionuclide Conjugates Basic Information
10.3.2 Lantheus Antibody-radionuclide Conjugates Product Overview
10.3.3 Lantheus Antibody-radionuclide Conjugates Product Market Performance
10.3.4 Lantheus Antibody-radionuclide Conjugates SWOT Analysis
10.3.5 Lantheus Business Overview
10.3.6 Lantheus Recent Developments
10.4 Aurobindo Pharma
10.4.1 Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information
10.4.2 Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview
10.4.3 Aurobindo Pharma Antibody-radionuclide Conjugates Product Market Performance
10.4.4 Aurobindo Pharma Business Overview
10.4.5 Aurobindo Pharma Recent Developments
10.5 Mundipharma
10.5.1 Mundipharma Antibody-radionuclide Conjugates Basic Information
10.5.2 Mundipharma Antibody-radionuclide Conjugates Product Overview
10.5.3 Mundipharma Antibody-radionuclide Conjugates Product Market Performance
10.5.4 Mundipharma Business Overview
10.5.5 Mundipharma Recent Developments
10.6 China Isotope and Radiation
10.6.1 China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information
10.6.2 China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview
10.6.3 China Isotope and Radiation Antibody-radionuclide Conjugates Product Market Performance
10.6.4 China Isotope and Radiation Business Overview
10.6.5 China Isotope and Radiation Recent Developments
10.7 Curium Pharmaceuticals
10.7.1 Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.7.2 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.7.3 Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.7.4 Curium Pharmaceuticals Business Overview
10.7.5 Curium Pharmaceuticals Recent Developments
10.8 Gilead Sciences
10.8.1 Gilead Sciences Antibody-radionuclide Conjugates Basic Information
10.8.2 Gilead Sciences Antibody-radionuclide Conjugates Product Overview
10.8.3 Gilead Sciences Antibody-radionuclide Conjugates Product Market Performance
10.8.4 Gilead Sciences Business Overview
10.8.5 Gilead Sciences Recent Developments
10.9 Clarity Pharmaceuticals
10.9.1 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.9.2 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.9.3 Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.9.4 Clarity Pharmaceuticals Business Overview
10.9.5 Clarity Pharmaceuticals Recent Developments
10.10 Curasight
10.10.1 Curasight Antibody-radionuclide Conjugates Basic Information
10.10.2 Curasight Antibody-radionuclide Conjugates Product Overview
10.10.3 Curasight Antibody-radionuclide Conjugates Product Market Performance
10.10.4 Curasight Business Overview
10.10.5 Curasight Recent Developments
10.11 Nordic Nanovector
10.11.1 Nordic Nanovector Antibody-radionuclide Conjugates Basic Information
10.11.2 Nordic Nanovector Antibody-radionuclide Conjugates Product Overview
10.11.3 Nordic Nanovector Antibody-radionuclide Conjugates Product Market Performance
10.11.4 Nordic Nanovector Business Overview
10.11.5 Nordic Nanovector Recent Developments
10.12 Philogen
10.12.1 Philogen Antibody-radionuclide Conjugates Basic Information
10.12.2 Philogen Antibody-radionuclide Conjugates Product Overview
10.12.3 Philogen Antibody-radionuclide Conjugates Product Market Performance
10.12.4 Philogen Business Overview
10.12.5 Philogen Recent Developments
10.13 RadioMedix
10.13.1 RadioMedix Antibody-radionuclide Conjugates Basic Information
10.13.2 RadioMedix Antibody-radionuclide Conjugates Product Overview
10.13.3 RadioMedix Antibody-radionuclide Conjugates Product Market Performance
10.13.4 RadioMedix Business Overview
10.13.5 RadioMedix Recent Developments
10.14 Telix Pharmaceuticals
10.14.1 Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.14.2 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.14.3 Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.14.4 Telix Pharmaceuticals Business Overview
10.14.5 Telix Pharmaceuticals Recent Developments
10.15 Orano Med
10.15.1 Orano Med Antibody-radionuclide Conjugates Basic Information
10.15.2 Orano Med Antibody-radionuclide Conjugates Product Overview
10.15.3 Orano Med Antibody-radionuclide Conjugates Product Market Performance
10.15.4 Orano Med Business Overview
10.15.5 Orano Med Recent Developments
10.16 Actinium Pharmaceuticals
10.16.1 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.16.2 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.16.3 Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.16.4 Actinium Pharmaceuticals Business Overview
10.16.5 Actinium Pharmaceuticals Recent Developments
10.17 Y-mAbs Therapeutics
10.17.1 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
10.17.2 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
10.17.3 Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Market Performance
10.17.4 Y-mAbs Therapeutics Business Overview
10.17.5 Y-mAbs Therapeutics Recent Developments
10.18 Fusion Pharmaceuticals
10.18.1 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
10.18.2 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
10.18.3 Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Market Performance
10.18.4 Fusion Pharmaceuticals Business Overview
10.18.5 Fusion Pharmaceuticals Recent Developments
11 ANTIBODY-RADIONUCLIDE CONJUGATES MARKET FORECAST BY REGION
11.1 Global Antibody-radionuclide Conjugates Market Size Forecast
11.2 Global Antibody-radionuclide Conjugates Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Antibody-radionuclide Conjugates Market Size Forecast by Country
11.2.3 Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region
11.2.4 South America Antibody-radionuclide Conjugates Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Antibody-radionuclide Conjugates by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Antibody-radionuclide Conjugates Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Antibody-radionuclide Conjugates by Type (2025-2032)
12.1.2 Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Antibody-radionuclide Conjugates by Type (2025-2032)
12.2 Global Antibody-radionuclide Conjugates Market Forecast by Application (2025-2032)
12.2.1 Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by Application
12.2.2 Global Antibody-radionuclide Conjugates Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antibody-radionuclide Conjugates Market Size Comparison by Region (M USD)
Table 5. Global Antibody-radionuclide Conjugates Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Antibody-radionuclide Conjugates Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antibody-radionuclide Conjugates Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-radionuclide Conjugates as of 2022)
Table 10. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antibody-radionuclide Conjugates Sales Sites and Area Served
Table 12. Manufacturers Antibody-radionuclide Conjugates Product Type
Table 13. Global Antibody-radionuclide Conjugates Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antibody-radionuclide Conjugates
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antibody-radionuclide Conjugates Market Challenges
Table 22. Global Antibody-radionuclide Conjugates Sales by Type (K MT)
Table 23. Global Antibody-radionuclide Conjugates Market Size by Type (M USD)
Table 24. Global Antibody-radionuclide Conjugates Sales (K MT) by Type (2019-2024)
Table 25. Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)
Table 26. Global Antibody-radionuclide Conjugates Market Size (M USD) by Type (2019-2024)
Table 27. Global Antibody-radionuclide Conjugates Market Size Share by Type (2019-2024)
Table 28. Global Antibody-radionuclide Conjugates Price (USD/MT) by Type (2019-2024)
Table 29. Global Antibody-radionuclide Conjugates Sales (K MT) by Application
Table 30. Global Antibody-radionuclide Conjugates Market Size by Application
Table 31. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (K MT)
Table 32. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)
Table 33. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (M USD)
Table 34. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)
Table 35. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
Table 36. Global Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 37. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)
Table 38. North America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 39. Europe Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 41. South America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 43. Global Antibody-radionuclide Conjugates Production (K MT) by Region (2019-2024)
Table 44. Global Antibody-radionuclide Conjugates Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)
Table 46. Global Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Bayer Antibody-radionuclide Conjugates Basic Information
Table 52. Bayer Antibody-radionuclide Conjugates Product Overview
Table 53. Bayer Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Bayer Business Overview
Table 55. Bayer Antibody-radionuclide Conjugates SWOT Analysis
Table 56. Bayer Recent Developments
Table 57. Novartis Antibody-radionuclide Conjugates Basic Information
Table 58. Novartis Antibody-radionuclide Conjugates Product Overview
Table 59. Novartis Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Novartis Business Overview
Table 61. Novartis Antibody-radionuclide Conjugates SWOT Analysis
Table 62. Novartis Recent Developments
Table 63. Lantheus Antibody-radionuclide Conjugates Basic Information
Table 64. Lantheus Antibody-radionuclide Conjugates Product Overview
Table 65. Lantheus Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Lantheus Antibody-radionuclide Conjugates SWOT Analysis
Table 67. Lantheus Business Overview
Table 68. Lantheus Recent Developments
Table 69. Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information
Table 70. Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview
Table 71. Aurobindo Pharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Aurobindo Pharma Business Overview
Table 73. Aurobindo Pharma Recent Developments
Table 74. Mundipharma Antibody-radionuclide Conjugates Basic Information
Table 75. Mundipharma Antibody-radionuclide Conjugates Product Overview
Table 76. Mundipharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Mundipharma Business Overview
Table 78. Mundipharma Recent Developments
Table 79. China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information
Table 80. China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview
Table 81. China Isotope and Radiation Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. China Isotope and Radiation Business Overview
Table 83. China Isotope and Radiation Recent Developments
Table 84. Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 85. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 86. Curium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Curium Pharmaceuticals Business Overview
Table 88. Curium Pharmaceuticals Recent Developments
Table 89. Gilead Sciences Antibody-radionuclide Conjugates Basic Information
Table 90. Gilead Sciences Antibody-radionuclide Conjugates Product Overview
Table 91. Gilead Sciences Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Gilead Sciences Business Overview
Table 93. Gilead Sciences Recent Developments
Table 94. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 95. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 96. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Clarity Pharmaceuticals Business Overview
Table 98. Clarity Pharmaceuticals Recent Developments
Table 99. Curasight Antibody-radionuclide Conjugates Basic Information
Table 100. Curasight Antibody-radionuclide Conjugates Product Overview
Table 101. Curasight Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Curasight Business Overview
Table 103. Curasight Recent Developments
Table 104. Nordic Nanovector Antibody-radionuclide Conjugates Basic Information
Table 105. Nordic Nanovector Antibody-radionuclide Conjugates Product Overview
Table 106. Nordic Nanovector Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. Nordic Nanovector Business Overview
Table 108. Nordic Nanovector Recent Developments
Table 109. Philogen Antibody-radionuclide Conjugates Basic Information
Table 110. Philogen Antibody-radionuclide Conjugates Product Overview
Table 111. Philogen Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Philogen Business Overview
Table 113. Philogen Recent Developments
Table 114. RadioMedix Antibody-radionuclide Conjugates Basic Information
Table 115. RadioMedix Antibody-radionuclide Conjugates Product Overview
Table 116. RadioMedix Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. RadioMedix Business Overview
Table 118. RadioMedix Recent Developments
Table 119. Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 120. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 121. Telix Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. Telix Pharmaceuticals Business Overview
Table 123. Telix Pharmaceuticals Recent Developments
Table 124. Orano Med Antibody-radionuclide Conjugates Basic Information
Table 125. Orano Med Antibody-radionuclide Conjugates Product Overview
Table 126. Orano Med Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Orano Med Business Overview
Table 128. Orano Med Recent Developments
Table 129. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 130. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 131. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Actinium Pharmaceuticals Business Overview
Table 133. Actinium Pharmaceuticals Recent Developments
Table 134. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
Table 135. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
Table 136. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Y-mAbs Therapeutics Business Overview
Table 138. Y-mAbs Therapeutics Recent Developments
Table 139. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 140. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 141. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. Fusion Pharmaceuticals Business Overview
Table 143. Fusion Pharmaceuticals Recent Developments
Table 144. Global Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
Table 145. Global Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
Table 146. North America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 147. North America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 148. Europe Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 149. Europe Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 150. Asia Pacific Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
Table 151. Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
Table 152. South America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 153. South America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 154. Middle East and Africa Antibody-radionuclide Conjugates Consumption Forecast by Country (2025-2032) & (Units)
Table 155. Middle East and Africa Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 156. Global Antibody-radionuclide Conjugates Sales Forecast by Type (2025-2032) & (K MT)
Table 157. Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032) & (M USD)
Table 158. Global Antibody-radionuclide Conjugates Price Forecast by Type (2025-2032) & (USD/MT)
Table 159. Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by Application (2025-2032)
Table 160. Global Antibody-radionuclide Conjugates Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Antibody-radionuclide Conjugates Market Size Comparison by Region (M USD)
Table 5. Global Antibody-radionuclide Conjugates Sales (K MT) by Manufacturers (2019-2024)
Table 6. Global Antibody-radionuclide Conjugates Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Antibody-radionuclide Conjugates Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-radionuclide Conjugates as of 2022)
Table 10. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Antibody-radionuclide Conjugates Sales Sites and Area Served
Table 12. Manufacturers Antibody-radionuclide Conjugates Product Type
Table 13. Global Antibody-radionuclide Conjugates Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Antibody-radionuclide Conjugates
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Antibody-radionuclide Conjugates Market Challenges
Table 22. Global Antibody-radionuclide Conjugates Sales by Type (K MT)
Table 23. Global Antibody-radionuclide Conjugates Market Size by Type (M USD)
Table 24. Global Antibody-radionuclide Conjugates Sales (K MT) by Type (2019-2024)
Table 25. Global Antibody-radionuclide Conjugates Sales Market Share by Type (2019-2024)
Table 26. Global Antibody-radionuclide Conjugates Market Size (M USD) by Type (2019-2024)
Table 27. Global Antibody-radionuclide Conjugates Market Size Share by Type (2019-2024)
Table 28. Global Antibody-radionuclide Conjugates Price (USD/MT) by Type (2019-2024)
Table 29. Global Antibody-radionuclide Conjugates Sales (K MT) by Application
Table 30. Global Antibody-radionuclide Conjugates Market Size by Application
Table 31. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (K MT)
Table 32. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)
Table 33. Global Antibody-radionuclide Conjugates Sales by Application (2019-2024) & (M USD)
Table 34. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)
Table 35. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
Table 36. Global Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 37. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)
Table 38. North America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 39. Europe Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 40. Asia Pacific Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 41. South America Antibody-radionuclide Conjugates Sales by Country (2019-2024) & (K MT)
Table 42. Middle East and Africa Antibody-radionuclide Conjugates Sales by Region (2019-2024) & (K MT)
Table 43. Global Antibody-radionuclide Conjugates Production (K MT) by Region (2019-2024)
Table 44. Global Antibody-radionuclide Conjugates Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Antibody-radionuclide Conjugates Revenue Market Share by Region (2019-2024)
Table 46. Global Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 47. North America Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 48. Europe Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 49. Japan Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 50. China Antibody-radionuclide Conjugates Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 51. Bayer Antibody-radionuclide Conjugates Basic Information
Table 52. Bayer Antibody-radionuclide Conjugates Product Overview
Table 53. Bayer Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 54. Bayer Business Overview
Table 55. Bayer Antibody-radionuclide Conjugates SWOT Analysis
Table 56. Bayer Recent Developments
Table 57. Novartis Antibody-radionuclide Conjugates Basic Information
Table 58. Novartis Antibody-radionuclide Conjugates Product Overview
Table 59. Novartis Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Novartis Business Overview
Table 61. Novartis Antibody-radionuclide Conjugates SWOT Analysis
Table 62. Novartis Recent Developments
Table 63. Lantheus Antibody-radionuclide Conjugates Basic Information
Table 64. Lantheus Antibody-radionuclide Conjugates Product Overview
Table 65. Lantheus Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 66. Lantheus Antibody-radionuclide Conjugates SWOT Analysis
Table 67. Lantheus Business Overview
Table 68. Lantheus Recent Developments
Table 69. Aurobindo Pharma Antibody-radionuclide Conjugates Basic Information
Table 70. Aurobindo Pharma Antibody-radionuclide Conjugates Product Overview
Table 71. Aurobindo Pharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 72. Aurobindo Pharma Business Overview
Table 73. Aurobindo Pharma Recent Developments
Table 74. Mundipharma Antibody-radionuclide Conjugates Basic Information
Table 75. Mundipharma Antibody-radionuclide Conjugates Product Overview
Table 76. Mundipharma Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. Mundipharma Business Overview
Table 78. Mundipharma Recent Developments
Table 79. China Isotope and Radiation Antibody-radionuclide Conjugates Basic Information
Table 80. China Isotope and Radiation Antibody-radionuclide Conjugates Product Overview
Table 81. China Isotope and Radiation Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. China Isotope and Radiation Business Overview
Table 83. China Isotope and Radiation Recent Developments
Table 84. Curium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 85. Curium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 86. Curium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Curium Pharmaceuticals Business Overview
Table 88. Curium Pharmaceuticals Recent Developments
Table 89. Gilead Sciences Antibody-radionuclide Conjugates Basic Information
Table 90. Gilead Sciences Antibody-radionuclide Conjugates Product Overview
Table 91. Gilead Sciences Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Gilead Sciences Business Overview
Table 93. Gilead Sciences Recent Developments
Table 94. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 95. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 96. Clarity Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Clarity Pharmaceuticals Business Overview
Table 98. Clarity Pharmaceuticals Recent Developments
Table 99. Curasight Antibody-radionuclide Conjugates Basic Information
Table 100. Curasight Antibody-radionuclide Conjugates Product Overview
Table 101. Curasight Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Curasight Business Overview
Table 103. Curasight Recent Developments
Table 104. Nordic Nanovector Antibody-radionuclide Conjugates Basic Information
Table 105. Nordic Nanovector Antibody-radionuclide Conjugates Product Overview
Table 106. Nordic Nanovector Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. Nordic Nanovector Business Overview
Table 108. Nordic Nanovector Recent Developments
Table 109. Philogen Antibody-radionuclide Conjugates Basic Information
Table 110. Philogen Antibody-radionuclide Conjugates Product Overview
Table 111. Philogen Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Philogen Business Overview
Table 113. Philogen Recent Developments
Table 114. RadioMedix Antibody-radionuclide Conjugates Basic Information
Table 115. RadioMedix Antibody-radionuclide Conjugates Product Overview
Table 116. RadioMedix Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. RadioMedix Business Overview
Table 118. RadioMedix Recent Developments
Table 119. Telix Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 120. Telix Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 121. Telix Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. Telix Pharmaceuticals Business Overview
Table 123. Telix Pharmaceuticals Recent Developments
Table 124. Orano Med Antibody-radionuclide Conjugates Basic Information
Table 125. Orano Med Antibody-radionuclide Conjugates Product Overview
Table 126. Orano Med Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Orano Med Business Overview
Table 128. Orano Med Recent Developments
Table 129. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 130. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 131. Actinium Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Actinium Pharmaceuticals Business Overview
Table 133. Actinium Pharmaceuticals Recent Developments
Table 134. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Basic Information
Table 135. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Product Overview
Table 136. Y-mAbs Therapeutics Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Y-mAbs Therapeutics Business Overview
Table 138. Y-mAbs Therapeutics Recent Developments
Table 139. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Basic Information
Table 140. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Product Overview
Table 141. Fusion Pharmaceuticals Antibody-radionuclide Conjugates Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. Fusion Pharmaceuticals Business Overview
Table 143. Fusion Pharmaceuticals Recent Developments
Table 144. Global Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
Table 145. Global Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
Table 146. North America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 147. North America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 148. Europe Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 149. Europe Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 150. Asia Pacific Antibody-radionuclide Conjugates Sales Forecast by Region (2025-2032) & (K MT)
Table 151. Asia Pacific Antibody-radionuclide Conjugates Market Size Forecast by Region (2025-2032) & (M USD)
Table 152. South America Antibody-radionuclide Conjugates Sales Forecast by Country (2025-2032) & (K MT)
Table 153. South America Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 154. Middle East and Africa Antibody-radionuclide Conjugates Consumption Forecast by Country (2025-2032) & (Units)
Table 155. Middle East and Africa Antibody-radionuclide Conjugates Market Size Forecast by Country (2025-2032) & (M USD)
Table 156. Global Antibody-radionuclide Conjugates Sales Forecast by Type (2025-2032) & (K MT)
Table 157. Global Antibody-radionuclide Conjugates Market Size Forecast by Type (2025-2032) & (M USD)
Table 158. Global Antibody-radionuclide Conjugates Price Forecast by Type (2025-2032) & (USD/MT)
Table 159. Global Antibody-radionuclide Conjugates Sales (K MT) Forecast by Application (2025-2032)
Table 160. Global Antibody-radionuclide Conjugates Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Antibody-radionuclide Conjugates
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antibody-radionuclide Conjugates Market Size (M USD), 2019-2032
Figure 5. Global Antibody-radionuclide Conjugates Market Size (M USD) (2019-2032)
Figure 6. Global Antibody-radionuclide Conjugates Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antibody-radionuclide Conjugates Market Size by Country (M USD)
Figure 11. Antibody-radionuclide Conjugates Sales Share by Manufacturers in 2023
Figure 12. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers in 2023
Figure 13. Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antibody-radionuclide Conjugates Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antibody-radionuclide Conjugates Market Share by Type
Figure 18. Sales Market Share of Antibody-radionuclide Conjugates by Type (2019-2024)
Figure 19. Sales Market Share of Antibody-radionuclide Conjugates by Type in 2023
Figure 20. Market Size Share of Antibody-radionuclide Conjugates by Type (2019-2024)
Figure 21. Market Size Market Share of Antibody-radionuclide Conjugates by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antibody-radionuclide Conjugates Market Share by Application
Figure 24. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)
Figure 25. Global Antibody-radionuclide Conjugates Sales Market Share by Application in 2023
Figure 26. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)
Figure 27. Global Antibody-radionuclide Conjugates Market Share by Application in 2023
Figure 28. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)
Figure 30. North America Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 32. U.S. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Antibody-radionuclide Conjugates Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Antibody-radionuclide Conjugates Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 37. Germany Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Antibody-radionuclide Conjugates Sales Market Share by Region in 2023
Figure 44. China Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 50. South America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 51. Brazil Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Antibody-radionuclide Conjugates Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Antibody-radionuclide Conjugates Production Market Share by Region (2019-2024)
Figure 62. North America Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 65. China Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Antibody-radionuclide Conjugates Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Antibody-radionuclide Conjugates Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Antibody-radionuclide Conjugates Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Antibody-radionuclide Conjugates Market Share Forecast by Type (2025-2032)
Figure 70. Global Antibody-radionuclide Conjugates Sales Forecast by Application (2025-2032)
Figure 71. Global Antibody-radionuclide Conjugates Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Antibody-radionuclide Conjugates
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Antibody-radionuclide Conjugates Market Size (M USD), 2019-2032
Figure 5. Global Antibody-radionuclide Conjugates Market Size (M USD) (2019-2032)
Figure 6. Global Antibody-radionuclide Conjugates Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Antibody-radionuclide Conjugates Market Size by Country (M USD)
Figure 11. Antibody-radionuclide Conjugates Sales Share by Manufacturers in 2023
Figure 12. Global Antibody-radionuclide Conjugates Revenue Share by Manufacturers in 2023
Figure 13. Antibody-radionuclide Conjugates Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Antibody-radionuclide Conjugates Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Antibody-radionuclide Conjugates Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Antibody-radionuclide Conjugates Market Share by Type
Figure 18. Sales Market Share of Antibody-radionuclide Conjugates by Type (2019-2024)
Figure 19. Sales Market Share of Antibody-radionuclide Conjugates by Type in 2023
Figure 20. Market Size Share of Antibody-radionuclide Conjugates by Type (2019-2024)
Figure 21. Market Size Market Share of Antibody-radionuclide Conjugates by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Antibody-radionuclide Conjugates Market Share by Application
Figure 24. Global Antibody-radionuclide Conjugates Sales Market Share by Application (2019-2024)
Figure 25. Global Antibody-radionuclide Conjugates Sales Market Share by Application in 2023
Figure 26. Global Antibody-radionuclide Conjugates Market Share by Application (2019-2024)
Figure 27. Global Antibody-radionuclide Conjugates Market Share by Application in 2023
Figure 28. Global Antibody-radionuclide Conjugates Sales Growth Rate by Application (2019-2024)
Figure 29. Global Antibody-radionuclide Conjugates Sales Market Share by Region (2019-2024)
Figure 30. North America Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 31. North America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 32. U.S. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 33. Canada Antibody-radionuclide Conjugates Sales (K MT) and Growth Rate (2019-2024)
Figure 34. Mexico Antibody-radionuclide Conjugates Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 36. Europe Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 37. Germany Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 38. France Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 39. U.K. Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 40. Italy Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 41. Russia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 42. Asia Pacific Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Antibody-radionuclide Conjugates Sales Market Share by Region in 2023
Figure 44. China Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 45. Japan Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 46. South Korea Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 47. India Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 48. Southeast Asia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 49. South America Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 50. South America Antibody-radionuclide Conjugates Sales Market Share by Country in 2023
Figure 51. Brazil Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 52. Argentina Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 53. Columbia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 54. Middle East and Africa Antibody-radionuclide Conjugates Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Antibody-radionuclide Conjugates Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 57. UAE Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 58. Egypt Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 59. Nigeria Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 60. South Africa Antibody-radionuclide Conjugates Sales and Growth Rate (2019-2024) & (K MT)
Figure 61. Global Antibody-radionuclide Conjugates Production Market Share by Region (2019-2024)
Figure 62. North America Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 63. Europe Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 64. Japan Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 65. China Antibody-radionuclide Conjugates Production (K MT) Growth Rate (2019-2024)
Figure 66. Global Antibody-radionuclide Conjugates Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Antibody-radionuclide Conjugates Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Antibody-radionuclide Conjugates Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Antibody-radionuclide Conjugates Market Share Forecast by Type (2025-2032)
Figure 70. Global Antibody-radionuclide Conjugates Sales Forecast by Application (2025-2032)
Figure 71. Global Antibody-radionuclide Conjugates Market Share Forecast by Application (2025-2032)
